FRM
NGM

Fox Run Management’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Fox Run Management’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-45,798
Closed -$230K – 983
2022
Q4 		$230K Buy
45,798
+34,352
+300% +$215K 0.09% 440
2022
Q3 		$150K Buy
11,446
+318
+3% +$4.82K 0.06% 521
2022
Q2 		$143K Buy
+11,128
New +$154K 0.07% 446

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

Fox Run Management's NGM Position: Q1 2023 in Review

Fox Run Management sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q1 2023, closing a stake of 45,798 shares — an estimated $230K sold.

Fox Run Management first reported a position in NGM in Q2 2022 and held it in 3 quarters. The position peaked at $230K in Q4 2022. 122 funds tracked by Wall St. Rank hold NGM as of Q1 2023.

  • Fox Run Management reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Fox Run Management sold 45,798 NGM Biopharmaceuticals, Inc. Common Stock shares in Q1 2023, an estimated $230K.
  • Fox Run Management first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2022 and held it in 3 quarters.
  • Fox Run Management's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $230K in Q4 2022.
  • 122 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q1 2023.

Based on Fox Run Management's 13F filing for Q1 2023, filed 12 May 2023.